Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus R-CHOP as first-line therapy for PD-L1-positive diffuse large B-cell lymphoma
ChiCTR2400088018Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in diffuse large B-cell lymphoma (DLBCL), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Objective response rate at 18 weeks, Complete remission rate at 24 months and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400088018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088018.